社区

In the newly announced entry list of the Inspiration Hive zone at the 2025 New York Society of Cosmetic Chemists (NYSCC) exhibition, Kintor’s innovative ingredient KT-939 has been selected as the only "Chinese ingredient" among the numerous global ones. It will compete with global industry giants such as Ashland, DSM-Firmenich, and Eastman, marking a groundbreaking milestone that China’s cosmetic ingredient R&D stands at the forefront of global innovation.

The 2025 NYSCC exhibition will open from 3rd June to 4th June at the Jacob Javits Convention Center in New York. As the world’s most influential B2B beauty industry event, NYSCC consistently sets trends for the global beauty and personal care sector, focusing on the integration of raw material supply chains and the communication of cutting-edge market trends and technologies. The Inspiration Hive zone was co-launched by global beauty trend authority BEAUTYSTREAMS and the NYSCC Suppliers’ Day. As the special zone in the NYSCC exhibition, Inspiration Hive aims to demonstrate the most forward-thinking and innovative ingredients and technologies in the beauty and personal care industry, emphasizing components and innovations aligned with future consumer trends.

Following its selection, KT-939 will be displayed alongside the pioneering products from global leaders like Ashland, DSM-Firmenich, Croda, Lubrizol, and Eastman, attracting attentions from key industry stakeholders across branding, R&D, and formulation and aligning with current hot trends such as sustainability, biotechnology, and personalized care. Meanwhile, the Inspiration Hive, as a high-end communication platform, will enable KT-939 to explore collaboration opportunities, establish new business connections, and drive partnerships and product development.

Inclusion in the Inspiration Hive zone underscores the company’s technological and innovative leadership, as well as KT-939’s superior efficacy and advantage in market trends. It represents a pivotal opportunity to enhance brand value and global influence, which will help strengthen industry credibility and professional recognition.

About Kintor Pharmaceutical Limited

Founded in 2009, Kintor Pharmaceutical Limited focuses on developing and commercializing potential "first-in-class" and "best-in-class" innovative drugs and functional cosmetics, aiming to be a leading enterprise in such areas, and establish a “troika” business model formed by R&D business of innovative topical drugs, B2B business of functional cosmetic raw materials and B2C business of functional cosmetic products. After several years' development, the Company has developed diverse product pipeline built on dermatology and oncology related diseases. The products cover diseases with high incidence rate globally and extend to functional cosmetics, which can meet the needs of clinical dermatology and cosmetics consumers worldwide. Kintor Pharma's layout includes innovative small molecule and biologic drugs, consisting of five productsunder clinical development and several preclinical research programs. Kintor Pharma has been granted more than 100 patents worldwide. On 22 May 2020, Kintor Pharma was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK. For more information, please visit www.kintor.com.cn.